Monti Paola, Campomenosi Paola, Ciribilli Yari, Iannone Raffaella, Aprile Anna, Inga Alberto, Tada Mitsuhiro, Menichini Paola, Abbondandolo Angelo, Fronza Gilberto
Mutagenesis Laboratory, National Cancer Research Institute (IST), Genova, Italy.
Oncogene. 2003 Aug 14;22(34):5252-60. doi: 10.1038/sj.onc.1206511.
p53 is the most frequently altered tumor suppressor gene in a wide spectrum of human tumors. The large majority of p53 mutations observed in tumors are missense mutations. The p73 gene, encoding a protein with significant sequence similarity to p53, expresses multiple transcription-competent spliced variants, or transcription-incompetent forms (i.e. DeltaNp73). It was clearly shown that p73 transactivation from a p53-responsive promoter is inhibited by some tumor-derived p53 mutants in eucaryotic cells. In this study, we adapted a yeast-based p53 functional assay for the analysis of the influences of different p53 mutants on the activity of one of the p73 isoforms, namely p73beta. We determined the ability of a panel of 61 p53 mutants to inhibit p73beta activity following the net transcription of the ADE2 color (red/white) reporter gene driven by a p53-responsive promoter. By analysing a large number of mutants, we could conclude that interference: (a) is a quite frequent phenomenon (more than 70% of p53 mutants analysed are interfering); (b) is not confined to p53 mutations located in particular topological regions of the DNA binding domain; (c) does not appear to be dependent on the kind of side chains introduced at a specific position; (d) appears to significantly correlate with evolutionary conservation of the mutated p53 codon, frequency of occurrence of the mutation in tumors. The influence of a common R/P polymorphism at codon 72 on the ability of p53 mutants to interfere with p73beta was also studied. Two sets of polymorphic variants (R and P) for 14 mutants were constructed and analysed. In all cases, the R/P 72 polymorphism was phenotypically irrelevant. In conclusion, our results suggest that the interpretation of the biological effects of p53 mutants should take into consideration the possibility that p53 mutants show loss or gain of function also through the interference with p53 family members.
p53是多种人类肿瘤中最常发生改变的肿瘤抑制基因。在肿瘤中观察到的绝大多数p53突变都是错义突变。p73基因编码一种与p53具有显著序列相似性的蛋白质,它表达多种具有转录活性的剪接变体或无转录活性的形式(即ΔNp73)。已有明确研究表明,在真核细胞中,一些肿瘤来源的p53突变体可抑制来自p53反应性启动子的p73反式激活。在本研究中,我们采用了一种基于酵母的p53功能检测方法,以分析不同p53突变体对p73亚型之一(即p73β)活性的影响。我们通过由p53反应性启动子驱动的ADE2颜色(红/白)报告基因的净转录,测定了一组61个p53突变体抑制p73β活性的能力。通过分析大量突变体,我们可以得出结论:干扰:(a)是一种相当常见的现象(超过70%被分析的p53突变体具有干扰作用);(b)并不局限于位于DNA结合域特定拓扑区域的p53突变;(c)似乎不依赖于在特定位置引入的侧链种类;(d)似乎与突变p53密码子的进化保守性、肿瘤中该突变的发生频率显著相关。我们还研究了密码子72处常见的R/P多态性对p53突变体干扰p73β能力的影响。构建并分析了14个突变体的两组多态性变体(R和P)。在所有情况下,72位的R/P多态性在表型上均无相关性。总之,我们的结果表明,在解释p53突变体的生物学效应时,应考虑到p53突变体也可能通过干扰p53家族成员而表现出功能丧失或获得的可能性。